Iovance Biotherapeutics

Iovance Biotherapeutics

Yahoo Finance • 23 days ago

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology. According to BioPharma Di... Full story

Yahoo Finance • 26 days ago

4 Biotech Stocks to Watch as Potential Takeover Targets

M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain access to promising technologies and late-... Full story

Yahoo Finance • 27 days ago

10 mid-cap healthcare stocks with the strongest momentum grades

Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector peers. Seeking Alpha's Quant Momentum... Full story

Yahoo Finance • last month

Most shorted stocks on Wall Street

[short sale] abluecup As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% of shares outst... Full story

Yahoo Finance • 2 months ago

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

An updated edition of the July 8, 2026, article. The global oncology market is undergoing significant transformation, driven by the rising burden of cancer, aging populations and rapid advances in medical science. According to the America... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations and Corporate Communications - Sara Pellegrino Interim CEO and President - Frederick Vogt Chief Fina... Full story

Yahoo Finance • 2 months ago

Why Investors Are Watching These Healthcare Movers

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.... Full story

Yahoo Finance • 2 months ago

Iovance surges as Amtagvi powers Q2 beat

[Green arrow pointing up and a dollar sign] Iovance Biotherapeutics (IOVA [https://seekingalpha.com/symbol/IOVA]) climbed more than 40% to reach a new 52-week high on Thursday after the company kept its revenue outlook under review follow... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltratin... Full story

Yahoo Finance • 3 months ago

Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data

(RTTNews) - Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy... Full story

Yahoo Finance • 3 months ago

This Stock Is Up 74% This Year: Is It Too Late to Buy?

Key Points Iovance Biotherapeutics is making strong regulatory and commercial progress with its key product. However, it faces several risks that could send the stock plummeting. 10 stocks we like better than Iovance Biotherapeutics › Af... Full story

Yahoo Finance • 3 months ago

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your portfolio today as you evaluate Heartflow Inc. (NASDAQ:HTFL) and Iovance Biothe... Full story

Yahoo Finance • 4 months ago

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers. Should inve... Full story

Yahoo Finance • 4 months ago

Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated followin... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 pr... Full story

Yahoo Finance • 4 months ago

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc... Full story

Yahoo Finance • 4 months ago

FDA Clears IND For Iovance's IOV-5001 In Treating Cancer; Phase 1/2 Enrollment Planned For H2 2026

(RTTNews) - Iovance Biotherapeutics Inc. (IOVA), a commercial-stage biopharmaceutical company, on Monday announced FDA clearance of the investigational new drug (IND) submission for IOV-5001, a tumor-infiltrating lymphocyte (TIL) therapy.... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focus... Full story

Yahoo Finance • 5 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies f... Full story